Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-day rivastigmine transdermal system versus daily Exelon patch crossover PK study
NL-OMON40916Active, not recruiting
- Sponsor
- Noven Pharmaceuticals
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) (3 arms), sponsored by Noven Pharmaceuticals. Primary endpoints: Plasma rivastigmine concentrations, Pharmacokinetic parameters and 10 more. Started Apr 2014; status: active, not recruiting.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NL-OMON40916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40916.